MedTrace Logo

Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor

NCT02562963 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-05-02

No results posted yet for this study

Summary

Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to determine whether Natural killer T (NKT) cells are effective and safe in the treatment of patients with unresectable advanced solid tumor.

Conditions

Interventions

BIOLOGICAL

natural killer T cell

The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.

Sponsors & Collaborators

  • Shanghai Public Health Clinical Center

    collaborator OTHER_GOV

  • First Hospital of Tsinghua University

    collaborator OTHER

  • Minghui Zhang

    lead OTHER

Principal Investigators

  • Minghui Zhang, PhD · Tsinghua University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2023-05-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02562963 on ClinicalTrials.gov